Bio-Rad Laboratories (BIO) experienced a significant 10.13% decline in post-market trading on Thursday. The sharp drop followed the release of the company's fourth-quarter financial results.

The life sciences company reported adjusted earnings per share of $2.51 for the quarter, missing the consensus estimate of $2.70 by 7.04%. This represents a 13.45% decrease from the $2.90 per share earned in the same period last year. While quarterly sales of $693.2 million slightly exceeded expectations, the earnings disappointment and year-over-year decline weighed heavily on investor sentiment.

Adding to concerns, Bio-Rad issued a conservative outlook for fiscal year 2026, projecting non-GAAP revenue growth of just 0.5% to 1.5%. The company cited ongoing challenges including geopolitical uncertainty and pressure on academic research funding, particularly noting a 2.6% decline in its Life Science segment sales due to constrained biotech funding.